Maternal and Fetal Delivery of Risdiplam Provides Partial Rescue in the SMNΔ7 Mouse Model of Spinal Muscular Atrophy
-
By
-
Emma R. Sutton
-
Ariane Beauvais
-
Rebecca Yaworski
-
Hugh J. McMillan
-
Rashmi Kothary
-
July 15, 2026
Clinical Scorecard: Maternal and Fetal Delivery of Risdiplam Provides Partial Rescue in the SMNΔ7 Mouse Model of Spinal Muscular Atrophy
At a Glance
| Category | Detail |
|---|
| Condition | Spinal Muscular Atrophy (SMA) |
| Key Mechanisms | Reduction in SMN protein due to mutations in the SMN1 gene. |
| Target Population | Pregnant women carrying fetuses at risk for SMA. |
| Care Setting | Research settings investigating prenatal therapeutic interventions. |
Key Highlights
- SMA is caused by mutations in the SMN1 gene leading to reduced SMN protein.
- Early intervention with disease-modifying therapies (DMTs) is crucial for favorable outcomes.
- Prenatal screening for SMA is increasingly implemented in various countries.
- In utero therapy has shown promise in animal models for improving SMA outcomes.
- Risdiplam has been administered prenatally with observed outcomes in a single case.
Guideline-Based Recommendations
Diagnosis
- Prenatal and newborn screening strategies can identify pre-symptomatic SMA.
Management
- Early postnatal treatment with DMTs is recommended for SMA.
Monitoring & Follow-up
- Monitor SMN protein levels and motor function development in SMA patients.
Risks
- Potential treatment-related congenital effects from prenatal therapy need further investigation.
Patient & Prescribing Data
Pregnant women with fetuses diagnosed or at risk for SMA.
Risdiplam administered prenatally may improve outcomes, but further studies are needed.
Clinical Best Practices
- Implement early diagnosis through prenatal screening.
- Consider prenatal therapeutic interventions where feasible.
- Monitor for developmental milestones in infants with SMA.
Related Resources & Content
